CLASS III ONGOING Drug recall · Reported 18 Jun 2025 · FDA Enforcement Report

Ezetimibe and Simvastatin Tablets, 10mg/40mg recalled

Glenmark Pharmaceuticals Inc., U is recalling Ezetimibe and Simvastatin Tablets, 10mg/40mg, distributed nationwide in the US. The recall was initiated on 19 May 2025 and the FDA has classified it as Class III.

Check your package

Lot, batch or date codesLot #: 17240195, Exp 01/31/2026.
NDC68462-321, 68462-322, 68462-323, 68462-324
UPC0368462321300, 0368462322307, 0368462323304
Quantity recalled6,759 Con - 90 bottle pack

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0462-2025
FDA event ID
96884
Recalling firm
Glenmark Pharmaceuticals Inc., U, Mahwah, NJ
Manufacturer
Glenmark Pharmaceuticals Inc., USA
Classification
Class III
Status
Ongoing
Recall initiated
19 May 2025
FDA classified
10 Jun 2025
Reported
18 Jun 2025
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

19 May 2025Recall initiated by company
10 Jun 2025Classified by FDA+22 days
18 Jun 2025Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed Impurities/Degradation Specifications: Out of Specification (OOS) for related substances test for Anhydro Simvastatin at the 06-month time point during long-term stability study.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Ezetimibe and Simvastatin Tablets, 10mg/40mg, 90-count bottle, Rx only, Manufactured by: Glenmark Pharmaceuticals Ltd., Plot No. 2, Phase-2, Pharma Zone SEZ, Madya Pradesh, India, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, NDC 68462-323-90

Where it was distributed

Nationwide USA and PR

Nationwide Puerto Rico

Questions about this recall

Is Ezetimibe and Simvastatin Tablets, 10mg/40mg recalled?

Yes. Glenmark Pharmaceuticals Inc., U recalled Ezetimibe and Simvastatin Tablets, 10mg/40mg on 19 May 2025. The recall is Class III and its status is Ongoing. Recall number D-0462-2025.

Why was it recalled?

Failed Impurities/Degradation Specifications: Out of Specification (OOS) for related substances test for Anhydro Simvastatin at the 06-month time point during long-term stability study.

Which lots are affected?

Lot #: 17240195, Exp 01/31/2026.

Where was it sold?

Nationwide USA and PR

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class III mean?

Class III recalls are for products unlikely to cause any adverse health consequence, usually labelling or quality issues.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Glenmark Pharmaceuticals Inc., U

All 141

Other Ezetimibe recalls

All 9